Overview

* DocGo Q3 2025 revenue beats analyst expectations despite a 49% yr/yr decline

* Adjusted EBITDA loss for Q3 2025 beats analyst estimates

* Net loss in Q3 2025 due to $16.7 mln non-cash impairments

* Company achieves record volumes across all major business lines

Outlook

* DocGo ( DCGO ) expects full-year 2025 revenue of $315-$320 mln

* Company anticipates full-year 2026 revenue of $280-$300 mln

* DocGo ( DCGO ) forecasts full-year 2025 adjusted EBITDA loss of $25-$28 mln

* Company projects full-year 2026 adjusted EBITDA loss of $15-$25 mln

Result Drivers

* MIGRANT PROGRAM WIND-DOWN - Revenue decline attributed to wind-down of migrant-related programs, impacting overall results

* CORE BUSINESS GROWTH - Excluding migrant-related programs, revenue increased 8% in core business lines

* RECORD VOLUMES - Achieved record volumes across all major business lines, with notable increases in care gap closure and transitions of care

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $70.81 $70 mln

Revenue mln (7

Analysts

)

Q3 EPS -$0.28

Q3 Net -$29.70

Income mln

Q3 Beat -$7.20 -$8.62

Adjusted mln mln (7

EBITDA Analysts

)

Q3 Gross 20.00%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for DocGo Inc ( DCGO ) is $3.00, about 63% above its November 7 closing price of $1.11

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)